Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005%
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Trial Timeline
Dec 6, 2015 → Feb 10, 2017
NCT ID
NCT02623738About Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005%
Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005% is a phase 2/3 stage product being developed by Santen Pharmaceutical for Primary Open Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02623738. Target conditions include Primary Open Angle Glaucoma, Ocular Hypertension.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02623738 | Phase 2/3 | Completed |
Competing Products
20 competing products in Primary Open Angle Glaucoma
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77